Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 7% – Should You Buy?

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shot up 7% during trading on Wednesday . The company traded as high as $4.31 and last traded at $4.3450. 406,910 shares were traded during trading, a decline of 89% from the average session volume of 3,840,116 shares. The stock had previously closed at $4.06.

Wall Street Analyst Weigh In

A number of research firms have weighed in on TSHA. Wells Fargo & Company raised their price target on Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Raymond James Financial assumed coverage on shares of Taysha Gene Therapies in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $13.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Moderate Buy” and a consensus price target of $10.30.

Taysha Gene Therapies Stock Performance

The company has a market cap of $1.19 billion, a price-to-earnings ratio of -13.20 and a beta of 1.06. The firm has a 50-day simple moving average of $4.42 and a 200 day simple moving average of $3.33. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. On average, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock in a transaction on Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the transaction, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 570,172 shares of company stock worth $2,341,906. Company insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several hedge funds have recently made changes to their positions in the business. Marex Group plc purchased a new position in shares of Taysha Gene Therapies during the second quarter worth about $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies during the 2nd quarter worth approximately $31,000. ST Germain D J Co. Inc. grew its stake in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares during the last quarter. May Hill Capital LLC acquired a new position in shares of Taysha Gene Therapies in the second quarter valued at approximately $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the third quarter worth approximately $40,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.